{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-011468","form_type":"8-K","ticker":"PLX","cik":"0001006281","company_name":"Protalix BioTherapeutics, Inc.","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.117111+00:00","generated_at":"2026-05-17T12:43:17.835604+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Protalix Q2 2025: Revenue $15.4M (+16% YoY), net income $164K; CFO transition, PRX-115 trial on track","bullets":["Revenue from goods $15.4M (+16% YoY); net income $164K vs $2.2M loss, EPS $0.00.","Elfabrio sales to Chiesi up $8M; EMA reviews label extension for every-4-weeks dosing.","CFO Eyal Rubin steps down Aug 24, replaced by Gilad Mamlok; transition through October.","PRX-115 Phase 2 for uncontrolled gout planned H2 2025; first patient enrollment Q4 2025.","Cash $33.4M; R&D doubled to $6M on PRX-115 prep; added to Russell 2000/3000 indexes."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-011468","json":"https://secwatch.observer/filing/0001558370-25-011468.json","markdown":"https://secwatch.observer/filing/0001558370-25-011468.md","text":"https://secwatch.observer/filing/0001558370-25-011468.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006281/000155837025011468/0001558370-25-011468-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006281/000155837025011468/plx-20250814x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T12:43:17.835604+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}